Current Report Filing (8-k)
February 01 2016 - 4:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 28, 2016
Illumina, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-35406 |
|
33-0804655 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
5200 Illumina Way, San Diego, California |
|
92122 |
(Address of principal executive offices) |
|
(Zip Code) |
(858) 202-4500
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
5.02(b)
On January 28, 2016, Jay T. Flatley, Chief Executive Officer of Illumina, Inc., was elected Chairman of the Board of Directors (the Board)
following the resignation of William H. Rastetter, Ph.D. The Board intends to appoint a lead independent director.
Dr. Rastetter stepped off the
Board after 17 years of service as a Board member and 11 years as Chairman, in compliance with Illumina governance practices, in order to invest in and serve as an Illumina representative on the board of directors of GRAIL, Inc. GRAIL is
Illuminas majority-owned subsidiary formed to enable cancer screening from a simple blood test powered by Illumina sequencing technology.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ILLUMINA, INC. |
|
|
|
|
Date: February 1, 2016 |
|
|
|
By: |
|
/s/ Charles E. Dadswell |
|
|
|
|
Charles E. Dadswell |
|
|
|
|
Senior Vice President, General Counsel and Secretary |
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024